PT-141
Also known as: Bremelanotide, Vyleesi
An FDA-approved melanocortin agonist for hypoactive sexual desire disorder.
Overview
PT-141 is a synthetic peptide melanocortin receptor agonist developed from Melanotan II. Unlike PDE5 inhibitors, it works through the central nervous system to enhance sexual desire and arousal.
Mechanism of Action
Activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, increasing sexual desire through central pathways. Works on desire/arousal rather than mechanical erectile function.
Pharmacokinetics
Peak effect 1-2 hours post-injection. Duration 24-72 hours. Half-life approximately 2.7 hours.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
As Needed
1.75 mg
45 min before activity
As needed
Max 8 doses per month; 1 dose per 24 hours
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1FDA-approved for premenopausal female HSDD (Vyleesi)
- 2Effective in men unresponsive to PDE5 inhibitors
- 3Works centrally on desire rather than peripherally
- 4Significant improvement in satisfying sexual events
Side Effects & Contraindications
Reported Side Effects
- Nausea (40%)
- Flushing
- Headache
- Injection site reactions
Contraindications
- Uncontrolled hypertension
- Cardiovascular disease
- Concurrent naltrexone
Safety Considerations
Common side effects include nausea and flushing. Contraindicated with uncontrolled hypertension. Limit to 8 doses monthly.
Storage Requirements
Store at room temperature. Protect from light.
Scientific References
- 1